Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC
Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.
Source: onclive.com
Egfr Mutant News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Egfr Mutant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Egfr Mutant Today - Breaking & Trending Today
COMING SOON: Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib
Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC.
Source: onclive.com
COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA
Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting.
Source: onclive.com
Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC
Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.
Source: onclive.com